Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis.
The Lancet ( IF 168.9 ) Pub Date : 2018-02-01 , DOI: 10.1016/s2213-8587(17)30412-6 M Angelyn Bethel , Rishi A Patel , Peter Merrill , Yuliya Lokhnygina , John B Buse , Robert J Mentz , Neha J Pagidipati , Juliana C Chan , Stephanie M Gustavson , Nayyar Iqbal , Aldo P Maggioni , Peter Öhman , Neil R Poulter , Ambady Ramachandran , Bernard Zinman , Adrian F Hernandez , Rury R Holman
The Lancet ( IF 168.9 ) Pub Date : 2018-02-01 , DOI: 10.1016/s2213-8587(17)30412-6 M Angelyn Bethel , Rishi A Patel , Peter Merrill , Yuliya Lokhnygina , John B Buse , Robert J Mentz , Neha J Pagidipati , Juliana C Chan , Stephanie M Gustavson , Nayyar Iqbal , Aldo P Maggioni , Peter Öhman , Neil R Poulter , Ambady Ramachandran , Bernard Zinman , Adrian F Hernandez , Rury R Holman
|
Glucagon-like peptide-1 (GLP-1) receptor agonists are effective glucose-lowering drugs. Findings from cardiovascular outcome trials showed cardiovascular safety of GLP-1 receptor agonists, but results for cardiovascular efficacy were varied. We aimed to examine overall cardiovascular efficacy for lixisenatide, liraglutide, semaglutide, and extended-release exenatide.
中文翻译：
胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管预后：一项荟萃分析。
胰高血糖素样肽-1（GLP-1）受体激动剂是有效的降糖药物。心血管结果试验的结果表明，GLP-1受体激动剂具有心血管安全性，但心血管功效的结果却各不相同。我们的目标是检查利西拉肽，利拉鲁肽，司马鲁肽和缓释艾塞那肽的总体心血管疗效。
更新日期：2018-01-24
中文翻译：
胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管预后：一项荟萃分析。
胰高血糖素样肽-1（GLP-1）受体激动剂是有效的降糖药物。心血管结果试验的结果表明，GLP-1受体激动剂具有心血管安全性，但心血管功效的结果却各不相同。我们的目标是检查利西拉肽，利拉鲁肽，司马鲁肽和缓释艾塞那肽的总体心血管疗效。
京公网安备 11010802027423号